**Name of journal:** ***World Journal of*** ***Gastroenterology***

**ESPS Manuscript NO: 32205**

**Manuscript Type: REVIEW**

**Role of autophagy in the pathogenesis of inflammatory bowel disease**

Iida T *et al.* IBD linked to autophagy

Tomoya Iida, Kei Onodera, Hiroshi Nakase

**Tomoya Iida, Kei Onodera, Hiroshi Nakase,** Department of Gastroenterology and Hepatology, Sapporo Medical University, School of Medicine, Hokkaido 060-8556, Japan

**Author contributions:** All authors helped to perform the research; Iida T wrote the paper; all authors have approved the final draft of the manuscript.

**Conflict-of-interest statement:** No potential conflicts of interest. No financial support.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Dr. Hiroshi Nakase,** Department of Gastroenterology and Hepatology, Sapporo Medical University, School of Medicine, Minami 1-jo Nishi 17-chome, Chuo-ku, Sapporo, Hokkaido 060-8556, Japan. hiropynakase@gmail.com

**Telephone**: +81-11-6112111

Fax: +81-11-6112282

**Received:** December 28, 2016

**Peer-review started:** December 29, 2016

**First decision:** January 19, 2017

**Revised:** February 7, 2017

**Accepted:** March 3, 2017

**Article in press:**

**Published online:**

**Abstract**

Inflammatory bowel disease (IBD) results from a complex series of interactions between susceptibility genes, the environment, and the immune system. Recently, some studies provided strong evidence that the process of autophagy affects several aspects of mucosal immune responses. Autophagy is a cellular stress response that plays key roles in physiological processes, such as innate and adaptive immunity, adaptation to starvation, degradation of aberrant proteins or organelles, antimicrobial defense, and protein secretion. Dysfunctional autophagy is recognized as a contributing factor in many chronic inflammatory diseases, including IBD. Autophagy plays multiple roles in IBD pathogenesis by altering processes that include intracellular bacterial killing, antimicrobial peptide secretion by Paneth cells, goblet cell function, proinflammatory cytokine production by macrophages, antigen presentation by dendritic cells, and the endoplasmic reticulum stress response in enterocytes. Recent studies have identified susceptibility genes involved in autophagy, such as *NOD2, ATG16L1*, and *IRGM*, and active research is ongoing all over the world. The aim of this review is a systematic appraisal of the current literature to provide a better understanding of the role of autophagy in the pathogenesis of IBD. Understanding these mechanisms will bring about new strategies for the treatment and prevention of IBD.

**Key words:** Autophagy; Inflammatory bowel disease; Ulcerative colitis; Crohn’s disease; Genome-wide association study

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Recent studies provide strong evidence that the process of autophagy affects several aspects of mucosal immune responses. Autophagy is a cellular stress response that plays key roles in physiological processes. Dysfunctional autophagy is recognized as a contributing factor in many chronic inflammatory diseases, including inflammatory bowel disease (IBD). Autophagy plays multiple roles in IBD pathogenesis. Recent studies have identified susceptibility genes involved in autophagy, such as *NOD2, ATG16L1*, and *IRGM*, and active research is ongoing around the world. The aim of this review is a systematic appraisal of current literature to provide a better understanding of the role of autophagy in IBD pathogenesis.

Tomoya Iida, Kei Onodera, Hiroshi Nakase. Role of autophagy in the pathogenesis of inflammatory bowel disease. *World J Gastroenterol* 2017; In press

**INTRODUCTION**

Inflammatory bowel disease (IBD) is a chronic inflammatory disease involving idiopathic inflammation, mainly in the gastrointestinal tract; defined more specifically, it comprises ulcerative colitis (UC) and Crohn’s disease (CD). Both are characterized by onset at a young age, and the number of affected patients has risen sharply in recent years in Europe and the United States, as well as in Japan[1]. Thus, there is a pressing need to understand their pathologies and create effective treatments. Researchers, mainly in Europe and the United States, have been trying to identify disease-susceptibility genes for IBD. Nucleotide-binding oligomerization domain-containing protein 2(*NOD2*) was the first susceptibility gene identified for CD[2,3], and in recent years genome-wide association studies (GWAS) have made it possible to perform comprehensive searches for susceptibility genes. In 2007, autophagy-related 16-like 1 (*ATG16L1*) was identified as an autophagy-related gene[4]. This was the first study to show a relationship between autophagy and a specific disease. Since then, the role of autophagy in the pathogenesis of IBD has been investigated all over the world.

This review will evaluate the current literature to provide a better understanding of the role of autophagy in the pathophysiology of IBD.

**PATHOLOGY AND PATHOGENESIS OF IBD**

The gastrointestinal tract not only absorbs fluid and nutrients, but is constantly involved in regulating and maintaining the gut flora, immune responses to food antigens and other substances, and homeostasis. IBD occurs when this homeostasis is impaired. Recent research has shown that IBD is caused by chronic intestinal inflammation, which occurs because of gene variations that can lead to disease susceptibility, changes in the structure of the intestinal flora needed to maintain intestinal homeostasis, and abnormal intestinal mucosal immune responses[5-7].

The role of genetic factors in IBD has been previously reported[8], and several researchers are seeking disease-susceptibility genes and trying to find customized treatments for individual patients[9]. To date, approximately 200 loci have been identified as being associated with both forms of IBD. Within these 200 loci, based upon single nucleotide polymorphism frequencies in IBD subjects versus controls, are approximately 1500 potential associated genes[10,11]. Representative autophagy-related genes are *NOD2*, *ATG16L1*, and immunity related guanosine triphosphatase M (*IRGM*)[1-3,12]. Autophagy has been linked to a variety of diseases, but its link to IBD is currently the subject of much debate.

**AUTOPHAGY**

Autophagy (from the Greek “auto” oneself and “phagy” to eat) refers to any cellular degradative pathway that involves the delivery of cytoplasmic cargo to the lysosome. During this process, the endoplasmic reticulum or other membranous cellular structures respond to stimuli by generating a double-membrane structure called a phagophore. On this phagophore, *ATG16L1* forms a complex with an *ATG5-ATG12* conjugate, which multimerizes and then lipidates *LC3 (LC3-II)*. Simultaneously, the phagophore elongates to envelop the cytoplasm or organelle to be degraded, forming an autophagosome, a unique double-membrane organelle. The outer membrane of the autophagosome then fuses with a lysosome to form an autolysosome, and the inner membrane degrades and absorbs its contents (Figure 1)[13-15]. This process, along with the ubiquitin proteasome pathway (UPP) system, triggers the intracellular protein degradation mechanism. The process is also responsible for mechanisms such as adaptation to starvation, defense against infections, carcinogenesis, antigen presentation, and quality control of intracellular proteins. It maintains appropriate cellular homeostasis and provides the structural processes necessary for organ renewal[16]. Yet, unlike the UPP system, autophagy is also able to degrade mitochondria and other organelles.

A remarkable analysis of autophagy-related factor groups showed that, in addition to its role in metabolism, autophagy plays an important role in the innate immune response[13]. Innate immunity is a mechanism by which nearly all multicellular organisms protect themselves from pathogens. Innate immunity signaling pathways are activated when the structural patterns of a pathogen’s components are recognized (i.e., the cell wall components of a bacterium or the genome of a virus). As noted above, autophagy was initially considered to be a nonspecific mechanism for degrading substances by incorporating them into a membrane structure, but recent research has shown that autophagosomes selectively isolate a variety of substrates[17]. However, besides autophagy of pathogens (xenophagy)[18,19] and autophagy of damaged mitochondria (mitophagy)[20,21], very little is understood about which substrates autophagy degrades when it functions as part of innate immunity.

**IBD- AND AUTOPHAGY-RELATED GENETIC VARIANTS**

Autophagic dysfunction causes several diseases[22-24], among which CD is being most extensively researched. The above mentioned GWAS found several genetic variants linked to CD onset, such as *NOD2* and *ATG16L1*. A summary of these variants is given below (Table 1).

***NOD2, ATG16L1***

*NOD2*, located on chromosome 16q12.1, was the first disease-susceptibility gene discovered for CD. Its genetic variants are common in European and American patients, but have not been found in Asian patients. *NOD2* is a pattern-recognition receptor that is involved in the homeostasis of intestinal immunity. It acts through mechanisms like autophagy, intracellular bacterial sensing, controlling the expression of the antibacterial peptide α-defensin in the Paneth cells of the small intestine, and improving immune tolerance by suppressing toll-like receptor (TLR) signals[25]. *NOD2* recruits the autophagy protein *ATG16L1* to the plasma membrane at the bacterial entry site; mutant *NOD2* failed to recruit *ATG16L1* to the plasma membrane and wrapping of invading bacteria by autophagosomes was impaired. Therefore, patients with CD with *NOD2* variants are considered to exhibit disorders of autophagy[26-28]. When the mechanism of autophagy is impaired, lipopolysaccharides and damage-associated molecular patterns trigger signaling by stimulating TLR and NOD-like receptors, tumor necrosis factor (TNF), and other inflammatory cytokines. They also stimulate caspase-1 causing interleukin (IL)-1β and IL-18 cleavage from precursors, which promotes extracellular secretion (inflammasomes). In an experiment using mice knocked out for *ATG16L,* which encodes *ATG16L1*, the protein necessary for the autophagic recruitment, TLR and TNF stimulation led to abnormal inflammasome activity in macrophages and other innate immunity cells[29].

*ATG16L1* is a homolog of *ATG16* that was first reported by Mizushima *et al*[30,31]. Along with *AT5* and *ATG12*, this molecule is required to form autophagosomes. Prescott *et al*[32] reported that the incidence of CD was likely to be two times higher in people with the T300A variant, an *ATG16L1* variant with a threonine-to-alanine substitution at amino-acid position 300. Later, a meta-analysis of 25 studies showed that T300A caused disease susceptibility to CD[33]. However, no significant difference was observed in an analysis of patients from Japan, South Korea, and China from 25 studies. This suggests that European and American patients exhibit different genetic factors compared to Asian patients, as is seen with *NOD2*. Moreover, a meta-analysis of 14 studies on UC reported an odds ratio of 1.06, or almost no difference[33].

The report that *ATG16L1* is a CD-susceptibility gene was a groundbreaking discovery suggesting a role for autophagy in the onset of IBD. Since then, several researchers have published studies on the link between *ATG16L1* and IBD.

Paneth cells are a specialized type of epithelial cell that are involved in innate immunity in the small intestine. When they come into contact with bacteria or other antigens, these cells release secretory granules containing antimicrobial peptides and a variety of proteins. In 2008, Cadwell *et al*[34] engineered a mouse with low expression of *ATG16L1* (Atg16L1HM mouse). Tissue analysis did not find lysozymes that are normally seen in the ileal mucosa, but found abnormal Paneth cell granule secretion. Moreover, they analyzed Paneth cells in non-inflamed areas of the ileum in patients with CD homozygous for the *ATG16L1* variant T300A, and found abnormal Paneth cells that strongly resembled those observed in Atg16L1HM mice. This suggests that *ATG16L1* may also play an important role by suppressing Paneth cells in humans. In a relatively recent study, Lassen *et al*[35] generated a knock-in mouse model expressing ATG16L1T300A. Such mice do not develop spontaneous inflammation, although they exhibit morphological defects in both Paneth cells and goblet cells. Furthermore, the presence of the T300A mutation in *ATG16L1* leads to aberrant functionality of Paneth cells. These findings indicate the reason there is believed to be a close relationship between *ATG16L1* variants and Paneth cells.

Further, Murthy *et al*[36] reported that *ATG16L1* amino-acid positions 296 to 299 form a caspase cleavage motif, which greatly increases *ATG16L1* sensitivity when the cellular stress response activates caspase-3 in the presence of the T300A variant. This may result in impaired autophagy, leading to CD onset, and suggests that *ATG16L1* plays a role at the molecular level in CD onset.

In 2010, Cadwell *et al*[37] reported interesting data on role of *ATG16L1* by using Atg16L1HM mice infected with MNV CR6, a species of mouse norovirus. MNV CR6-infected Atg16L1HM mice showed abnormal secretion of Paneth cell granules, similar to that described above. This was not observed in wild-type mice without an *ATG16L1* variant, or in mice infected with a different MNV strain or with inactivated MNV. Administration of dextran sulfate sodium (DSS) to these infected mice led to pathology similar to that observed in human patients with CD: inflammation extending to the muscle layer and mesentery, and atrophy of the ileal villi, neither of which has been previously reported with DSS colitis. These symptoms were significantly suppressed by administering TNF-α antibodies or antibiotics. A recent report suggested that *ATG16L1* polymorphisms promote disease through defects in "sensing" protective signals from the microbiome, defining a potentially critical gene-environment etiology for IBD[38].

These data suggest that in addition to *ATG16L1* variants, CD onset is influenced by a complex variety of environmental factors, including viral infections and enterobacteria.

***IRGM***

In a 2007 GWAS, Parkes *et al*[39] reported that the *IRGM* gene on chromosome 5q33.1 was a CD-susceptibility gene. In humans, *IRGM* is a 20 kDa protein formed from 181 amino acids that is expressed in the large intestine, small intestine, and lymphocytes. *IRGM* is related to bacterial killing, vacuolar trafficking and acidification, phagosome maturation, and virus-induced autophagy. Moreover, it is known to be involved in controlling intracellular *Mycobacterium tuberculosis* by autophagy in macrophages[40]. A small nuclear polymorphism (SNP) with susceptibility is adjacent to *IRGM*, but detailed sequencing of *IRGM* did not reveal any CD-related variants with modified amino acids. This suggests the possibility that changes of *IRGM* expression, transcript splicing, or the ratio of translation of the protein are related to the development of CD.

In 2008, McCarroll *et al*[41] discovered a 20 kb deletion polymorphism upstream from *IRGM* that was linked to an SNP correlating with CD. In addition, they reported that the expression of *IRGM* suppressed autophagy of intracellular bacteria, which has been linked to CD, suggesting a role in the pathology of CD.

Recently, Rufini *et al*[42] reported that *IRGM* polymorphisms were important for Crohn's disease susceptibility and phenotype modulation (fibrostricturing behavior, ileal disease, perianal disease, and intestinal resection).

***IL-23R***

IL-23 is a heterodimeric cytokine produced by activated macrophages and dendritic cells. It consists of two subunits, a p40 subunit, shared with IL-12, and a specific IL-23 subunit called p19[43,44]. It has been shown that IL-23 is involved in the initiation of the innate and adaptive immune activation that characterizes IBD. It binds a complex of IL-23 receptor (IL-23R) and IL-12Rβ subunits. *IL-23R* is predominantly expressed on activated/memory T cells, T-cell clones, natural killer cells and, at low levels, in monocytes, macrophages, and dendritic cell populations[45,46]. Recent studies have shown association of the *IL-23R* gene with chronic inflammatory diseases, especially IBD[47,48]. It is also reported that autophagy regulates IL-23 secretion and innate T cell responses through effects on IL-1 secretion[49].

***XIAP***

X-linked inhibitor of apoptosis (*XIAP*) is one of several inhibitor of apoptosis proteins (IAPs). IAPs were initially identified in baculoviruses, where they prevent defensive apoptosis of host cells[50].Among the mammalian IAPs, *XIAP* is the most extensively studied and best characterized. *XIAP* has the most potent anti-apoptotic ability[51], which is believed to be primarily related to direct binding and inhibiting of caspases, the apoptotic proteases that are responsible for the initiation and execution of apoptosis[52]. Huang *et al*[53] showed that *XIAP* is a physiological inhibitor of autophagy, and has been associated with a variety of diseases that have been linked to autophagy. *XIAP* is related to X-linked lymphoproliferative syndrome type 2 (XLP2), a type of primary immunodeficiency. However, a genetic analysis performed by Zeissiq *et al*[54] found *XIAP* variants in only 4% of male patients with childhood-onset Crohn’s disease. Recently, Schwerd *et al*[55] showed impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann-Pick disease type C1 and *XIAP* deficiency with *NOD2* variants in CD.

***LRRK2***

Leucine-rich repeat kinase 2 (*LRRK2*) is a large multidomain protein belonging to the ROCO family of proteins, which are characterized by the presence of leucine-rich repeats, a Ras of complex (ROC) GTPase domain, a C-terminal ROC linker region, and a kinase domain. *LRRK2* localizes to specific membrane subdomains, including endolysosomal structures in many kinds of cells. Studies showed that *LRRK2* KO mice displayed an increase in the number and size of secondary lysosomes and autolysosome-like structures. Abnormal accumulation of undigested material indicates an impairment in the autophagosomal-lysosomal degradation system (autophagy-lysosomal clearance pathway).

*LRRK2* has been identified as a disease-susceptibility gene for Parkinson’s disease, leprosy, and CD. The CD-associated SNP is located upstream of the coding sequence of *LRRK2*[56, 57]. It was reported that *LRRK2* expression levels were found to be significantly upregulated in colonic biopsy specimens from inflamed tissues of patients with CD[58]. *LRRK2* is known to be expressed only in mucosal lymphocytes in the colonic mucosa, but little else is known about it.

***ULK1***

Unc-51 like autophagy activating kinase 1 (*ULK1*) is one of the key regulators of autophagy initiation and progression. Mammals have two homologs of the yeast autophagy-initiating ATG1 kinase, *ULK1* and *ULK2*. *ULK1* is regulated by the nutrient- and energy-sensitive kinases TORC1 and AMPK. The tight regulation of ULK activity by intracellular energy and nutrient levels is in keeping with a central role for autophagy in the protection of cells from starvation.

Henkaerts *et al*[59] selected human homologs of 12 yeast autophagy genes, known to be found in IBD-related loci from GWAS, and conducted a meta-analysis of these searches. An analysis of correlations with CD identified *ULK1* as a CD-susceptibility gene. *ULK1* activity is regulated by a complex array of multiple phosphorylation and dephosphorylation events that influence the binding of regulatory and effector autophagy proteins[60, 61]. However, little is known about the action of *ULK1* in association with IBD, and further research is necessary.

***VDR***

The vitamin D receptor (*VDR*) regulates the expression of *NOD2*,and it has been suggested that it controls the mechanism of autophagy. Unlike other genes, *VDR* has been shown to be a UC-susceptibility gene, not only among Europeans and Americans, but also in Asian and Middle Eastern populations[62]. Vitamin D deficiency increases the risk of CD onset[63]; thus, analyzing its signaling pathways could help elucidate the pathology of this disease.

Recently, Wu *et al*[64] showed a fundamental relationship between the *VDR*, autophagy, and gut microbial assemblage that is essential for maintaining intestinal homeostasis, but also contributes to the pathophysiology of IBD. Furthermore, Abreu-Delgado *et al*[65] reported that levels of serum vitamin D correlate positively with colonic *VDR* expression in visually normal mucosa; whereas inflammation correlates negatively with colonic *VDR* expression in visually diseased mucosa. The *VDR* needs further research.

***MTMR3***

Myotubularin-related protein 3 (*MTMR3*) plays a role in autophagosome formation[66].The myotubularin family is a class of PI3-phosphatases that regulate several physiological and pathophysiological phenomena, including endosomal trafficking, apoptosis, autophagy, and muscle development.As a member of this family, *MTMR3* has been considered to play a negative role in the initiation stage of autophagy. Recent reports indicate that *MTMR3* has at least two opposite functions in the autophagy pathway, inhibition of mTORC1 and reduction of local PI3P levels[67,68]. In this regard, the function of *MTMR3* in autophagy remains unclear.

**ROLE OF AUTOPHAGY IN IBD THERAPY AND FUTURE PROSPECTS**

Widely used therapeutic agents for IBD include steroids and 5-aminosalicylic acid (5-ASA), as well as immunoregulatory drugs such as azathioprine, and biologicals such as anti-TNF-α formulations. The process of autophagy is closely related to each of these existing therapeutic agents. The following sections summarize these relationships (Table 2).

***5-ASA***

The mechanism of action of 5-ASA has been described in several studies. The suppression of peroxisome proliferator-activated receptor gamma (PPARγ) due to the production of inflammatory cytokines is said to contribute to the intestinal inflammation seen in patients with IBD[69]. 5-ASA is considered to exert its anti-inflammatory action by acting on PPARγ in epithelial cells, and by regulating signal transmission from NF-κB and TLR[70]. Considering that NF-κB signaling is associated with autophagy[71], it might be that 5-ASA indirectly regulates autophagy.

***Corticosteroids***

The first-line treatment to induce remission for CD and UC is often corticosteroids. Corticosteroids downregulate proinflammatory cytokines, including IL-1, IL-6, and TNFα. Furthermore, inflammatory signaling induced by NF-κB is decreased by interaction with corticosteroid receptors[72], and, as noted above, NF-κB signaling regulates autophagy[71]. It has also been shown that corticosterone treatment affects mechanistic target of rapamycin complex 1 (mTORC1) signaling pathways[73]. It was reported that mTORC1 pathways and autophagy play an important role in the response to treatment with corticosteroids[74]. Corticosteroids are able to induce apoptosis in immature T lymphocytes, as these cells lack the inhibitor of apoptosis protein Bcl-2. It has been shown that overexpression of Bcl-2 in immature T lymphocytes can increase autophagy levels, presumably due to inhibition of apoptosis[75].

A relationship between corticosteroids and autophagy has been observed, not only for their therapeutic effects, but also for the adverse effects that accompany treatment. It has been shown, both in vitro and in vivo, that low doses of prednisolone and dexamethasone induce autophagy in osteocytes, and this is associated with osteocyte viability[76,77]. However, higher doses of corticosteroids induce apoptosis, suggesting that autophagy may act as a protective mechanism against the cytotoxic effects of corticosteroids[76].

***Thiopurines (azathioprine and 6-mercaptopurine)***

Thiopurines, including azathioprine and 6-mercaptopurine, are immunosuppressant drugs used to maintain remission in patients with IBD[78]. Thiopurines and autophagy have also been shown to be correlated by the adverse effects of treatment. The thiopurine S-methyltransferase (*TPMT*) genetic polymorphism is important for thiopurine metabolism. Individuals with inherited decreases in TPMT activity, mainly as a result of the effects of the TPMT\*3A allele (minor allele frequency in Caucasians of approximately 5%)[79], are at greatly increased risk for severe life-threatening myelosuppression when treated with “standard” doses of thiopurine drugs[80-83]. It was shown that autophagy might represent an important route for the clearance of TPMT\*3A aggregates and/or aggregate precursors[84]. Due to the severe adverse effects of thiopurines, a potential protective role for autophagy in hepatocytes has been investigated; it has been shown that autophagy has a protective role in hepatocytes during thiopurine therapy[78].

***Immunomodulatory drugs (cyclosporine A, FK506, methotrexate)***

Cyclosporine A (CsA), FK506, and methotrexate (MTX) are immunomodulatory drugs used mainly as second-line treatments to induce and maintain remission in severe, steroid-refractory CD[85], with more recent evidence suggesting a role for FK506 in UC[86]. Although some evidence suggests that CsA and FK506 are involved in autophagy, no relationship has been identified between MTX and autophagy.

Several studies have shown that treatment with CsA can induce autophagy in response to toxicity (such as CsA-induced nephrotoxicity), either as a survival process or as part of a cell death mechanism[87-89].

FK506 inhibits calcineurin by forming a complex with the immunophilin FK506 binding protein 12 (FKBP12), which is involved in immunoregulation[90]. FKBP12 is also the direct target of rapamycin, an inhibitor of mTORC1. The molecular mechanism by which mTORC1 regulates autophagy in mammals is being investigated[91,92], while future research is expected to help understand the relationship between FK506 and autophagy.

***Biological drugs (infliximab, adalimumab, etc.)***

The most commonly used biological drug for IBD is the anti-TNFα antibody infliximab. Other anti-TNFα treatments approved for treatment of patients with IBD patients include adalimumab, golimumab for UC only, and certolizumab pegol. Anti-TNFα biosimilars have also recently been developed[93]. The relationship between TNFα and autophagy has been confirmed in synovial fibroblasts[94], skeletal muscles[95], and trophoblastic cells[96]. These studies suggest that anti-TNF agents would inhibit autophagy, and while the mechanism of action is not yet completely clear, it has been the subject of extensive research lately.

The above data summarizes the relationship between autophagy and various drugs. However, existing medical therapies do not relieve the symptoms in many patients, and surgical intervention is often necessary. There is, therefore, a pressing need to develop new therapeutic agents. As seen in this review, autophagy plays an important role in controlling the immune system; hence drugs that regulate autophagy have received much attention as potential new therapeutic targets for IBD[97]. Further investigation of the role of autophagy in existing IBD therapies, and development of new therapeutic agents regulating autophagy, are the needs of the hour.

**CONCLUSION**

GWAS has identified several disease-susceptibility genes, and studies on the pathology and etiology of IBD are being regularly published; however, more aspects of IBD pathogenesis should be clarified. As the number of patients with IBD is still increasing around the world, particularly among the young, it is essential that the mechanism of IBD is elucidated and treatments based on this mechanism are developed. A better understanding of the relationship between autophagy and IBD will result in better IBD therapy in future.

**REFERENCES**

1 **Molodecky NA**, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology* 2012; **142**: 46-54.e42; quiz e30 [PMID: 22001864 DOI: 10.1053/j.gastro.2011.10.001]

2 **Hugot JP**, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. *Nature* 2001; **411**: 599-603 [PMID: 11385576 DOI: 10.1038/35079107]

3 **Ogura Y**, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nuñez G, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. *Nature* 2001; **411**: 603-606 [PMID: 11385577 DOI: 10.1038/35079114]

4 **Hampe J**, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, Albrecht M, Mayr G, De La Vega FM, Briggs J, Günther S, Prescott NJ, Onnie CM, Häsler R, Sipos B, Fölsch UR, Lengauer T, Platzer M, Mathew CG, Krawczak M, Schreiber S. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. *Nat Genet* 2007; **39**: 207-211 [PMID: 17200669 DOI: 10.1038/ng1954]

5 **Kaser A**, Blumberg RS. Autophagy, microbial sensing, endoplasmic reticulum stress, and epithelial function in inflammatory bowel disease. *Gastroenterology* 2011; **140**: 1738-1747 [PMID: 21530740 DOI: 10.1053/j.gastro.2011.02.048]

6 **Kaser A**, Zeissig S, Blumberg RS. Inflammatory bowel disease. *Annu Rev Immunol* 2010; **28**: 573-621 [PMID: 20192811 DOI: 10.1146/annurev-immunol-030409-101225]

7 **Khor B**, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. *Nature* 2011; **474**: 307-317 [PMID: 21677747 DOI: 10.1038/nature10209]

8 **Weterman IT**, Peña AS. Familial incidence of Crohn's disease in The Netherlands and a review of the literature. *Gastroenterology* 1984; **86**: 449-452 [PMID: 6693011]

9 **Fiocchi C**. Tailoring Treatment to the Individual Patient - Will Inflammatory Bowel Disease Medicine Be Personalized? *Dig Dis* 2015; **33** Suppl 1: 82-89 [PMID: 26368553 DOI: 10.1159/000437086]

10 **Cho JH**, Brant SR. Recent insights into the genetics of inflammatory bowel disease. *Gastroenterology* 2011; **140**: 1704-1712 [PMID: 21530736 DOI: 10.1053/j.gastro.2011.02.046]

11 **Ek WE**, D'Amato M, Halfvarson J. The history of genetics in inflammatory bowel disease. *Ann Gastroenterol* 2014; **27**: 294-303 [PMID: 25331623]

12 **Goldstein DB**. Common genetic variation and human traits. *N Engl J Med* 2009; **360**: 1696-1698 [PMID: 19369660 DOI: 10.1056/NEJMp0806284]

13 **Jostins L,** Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton A, Boucher G, Brand S, Büning C, Cohain A, Cichon S, D’Amato M, De Jong D, Devaney KL, Dubinsky M, Edwards C, Ellinghaus D, Ferguson LR, Franchimont D, Fransen K, Gearry R, Georges M, Gieger C, Glas J, Haritunians T, Hart A, Hawkey C, Hedl M, Hu X, Karlsen TH, Kupcinskas L, Kugathasan S, Latiano A, Laukens D, Lawrance IC, Lees CW, Louis E, Mahy G, Mansfield J, Morgan AR, Mowat C, Newman W, Palmieri O, Ponsioen CY, Potocnik U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, Sanderson JD, Sans M, Satsangi J, Schreiber S, Simms LA, Sventoraityte J, Targan SR, Taylor KD, Tremelling M, Verspaget HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, Xavier RJ, Zeissig S, Zhang B, Zhang CK, Zhao H; International IBD Genetics Consortium (IIBDGC), Silverberg MS, Annese V, Hakonarson H, Brant SR, Radford-Smith G, Mathew CG, Rioux JD, Schadt EE, Daly MJ, Franke A, Parkes M, Vermeire S, Barrett JC, Cho JH. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature* 2012; **491**: 119–124 [PMID: 23128233 DOI: 10.1038/nature11582]

14 **Levine B**, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. *Nature* 2011; **469**: 323-335 [PMID: 21248839 DOI: 10.1038/nature09782]

15 **Hooper KM**, Barlow PG, Stevens C, Henderson P. Inflammatory Bowel Disease Drugs: A Focus on Autophagy. *J Crohns Colitis* 2017; **11**: 118-127 [PMID: 27381462 DOI: 10.1093/ecco-jcc/jjw127]

16 **Levine B**, Kroemer G. Autophagy in the pathogenesis of disease. *Cell* 2008; **132**: 27-42 [PMID: 18191218 DOI: 10.1016/j.cell.2007.12.018]

17 **Mizushima N**, Yoshimori T, Ohsumi Y. The role of Atg proteins in autophagosome formation. *Annu Rev Cell Dev Biol* 2011; **27**: 107-132 [PMID: 21801009 DOI: 10.1146/annurev-cellbio-092910-154005]

18 **Levine B**. Eating oneself and uninvited guests: autophagy-related pathways in cellular defense. *Cell* 2005; **120**: 159-162 [PMID: 15680321 DOI: 10.1016/j.cell.2005.01.005]

19 **Nozawa T**, Minowa-Nozawa A, Aikawa C, Nakagawa I. The STX6-VTI1B-VAMP3 complex facilitates xenophagy by regulating the fusion between recycling endosomes and autophagosomes. *Autophagy* 2017; **13**: 57-69 [PMID: 27791468 DOI: 10.1080/15548627.2016.1241924]

20 **Hailey DW**, Rambold AS, Satpute-Krishnan P, Mitra K, Sougrat R, Kim PK, Lippincott-Schwartz J. Mitochondria supply membranes for autophagosome biogenesis during starvation. *Cell* 2010; **141**: 656-667 [PMID: 20478256 DOI: 10.1016/j.cell.2010.04.009]

21 **Yao Z**, Klionsky DJ. An unconventional pathway for mitochondrial protein degradation. *Autophagy* 2016; **12**: 1971-1972 [PMID: 27686525 DOI: 10.1080/15548627.2016.1235127]

22 **Guo R**, Lin B, Pan JF, Liong EC, Xu AM, Youdim M, Fung ML, So KF, Tipoe GL. Inhibition of caspase-9 aggravates acute liver injury through suppression of cytoprotective autophagy. *Sci Rep* 2016; **6**: 32447 [PMID: 27580936 DOI: 10.1038/srep32447]

23 **Kang YH**, Cho MH, Kim JY, Kwon MS, Peak JJ, Kang SW, Yoon SY, Song Y. Impaired macrophage autophagy induces systemic insulin resistance in obesity. *Oncotarget* 2016; **7**: 35577-35591 [PMID: 27229537 DOI: 10.18632/oncotarget.9590]

24 **Martinez J**, Cunha LD, Park S, Yang M, Lu Q, Orchard R, Li QZ, Yan M, Janke L, Guy C, Linkermann A, Virgin HW, Green DR. Noncanonical autophagy inhibits the autoinflammatory, lupus-like response to dying cells. *Nature* 2016; **533**: 115-119 [PMID: 27096368 DOI: 10.1038/nature17950]

25 **Yano T**, Kurata S. Intracellular recognition of pathogens and autophagy as an innate immune host defence. *J Biochem* 2011; **150**: 143-149 [PMID: 21729928 DOI: 10.1093/jb/mvr083]

26 **Cooney R**, Baker J, Brain O, Danis B, Pichulik T, Allan P, Ferguson DJ, Campbell BJ, Jewell D, Simmons A. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. *Nat Med* 2010; **16**: 90-97 [PMID: 19966812 DOI: 10.1038/nm.2069]

27 **Homer CR**, Richmond AL, Rebert NA, Achkar JP, McDonald C. ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn's disease pathogenesis. *Gastroenterology* 2010; **139**: 1630-141, 1630-141, [PMID: 20637199 DOI: 10.1053/j.gastro.2010.07.006]

28 **Travassos LH**, Carneiro LA, Ramjeet M, Hussey S, Kim YG, Magalhães JG, Yuan L, Soares F, Chea E, Le Bourhis L, Boneca IG, Allaoui A, Jones NL, Nuñez G, Girardin SE, Philpott DJ. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. *Nat Immunol* 2010; **11**: 55-62 [PMID: 19898471 DOI: 10.1038/ni.1823]

29 **Saitoh T**, Fujita N, Jang MH, Uematsu S, Yang BG, Satoh T, Omori H, Noda T, Yamamoto N, Komatsu M, Tanaka K, Kawai T, Tsujimura T, Takeuchi O, Yoshimori T, Akira S. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. *Nature* 2008; **456**: 264-268 [PMID: 18849965 DOI: 10.1038/nature07383]

30 **Mizushima N**, Noda T, Ohsumi Y. Apg16p is required for the function of the Apg12p-Apg5p conjugate in the yeast autophagy pathway. *EMBO J* 1999; **18**: 3888-3896 [PMID: 10406794 DOI: 10.1093/emboj/18.14.3888]

31 **Mizushima N**, Kuma A, Kobayashi Y, Yamamoto A, Matsubae M, Takao T, Natsume T, Ohsumi Y, Yoshimori T. Mouse Apg16L, a novel WD-repeat protein, targets to the autophagic isolation membrane with the Apg12-Apg5 conjugate. *J Cell Sci* 2003; **116**: 1679-1688 [PMID: 12665549]

32 **Prescott NJ**, Fisher SA, Franke A, Hampe J, Onnie CM, Soars D, Bagnall R, Mirza MM, Sanderson J, Forbes A, Mansfield JC, Lewis CM, Schreiber S, Mathew CG. A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn's disease and is independent of CARD15 and IBD5. *Gastroenterology* 2007; **132**: 1665-1671 [PMID: 17484864 DOI: 10.1053/j.gastro.2007.03.034]

33 **Cheng JF**, Ning YJ, Zhang W, Lu ZH, Lin L. T300A polymorphism of ATG16L1 and susceptibility to inflammatory bowel diseases: a meta-analysis. *World J Gastroenterol* 2010; **16**: 1258-1266 [PMID: 20222171]

34 **Cadwell K**, Liu JY, Brown SL, Miyoshi H, Loh J, Lennerz JK, Kishi C, Kc W, Carrero JA, Hunt S, Stone CD, Brunt EM, Xavier RJ, Sleckman BP, Li E, Mizushima N, Stappenbeck TS, Virgin HW. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. *Nature* 2008; **456**: 259-263 [PMID: 18849966 DOI: 10.1038/nature07416]

35 **Lassen KG**, Kuballa P, Conway KL, Patel KK, Becker CE, Peloquin JM, Villablanca EJ, Norman JM, Liu TC, Heath RJ, Becker ML, Fagbami L, Horn H, Mercer J, Yilmaz OH, Jaffe JD, Shamji AF, Bhan AK, Carr SA, Daly MJ, Virgin HW, Schreiber SL, Stappenbeck TS, Xavier RJ. Atg16L1 T300A variant decreases selective autophagy resulting in altered cytokine signaling and decreased antibacterial defense. *Proc Natl Acad Sci U S A* 2014; **111**: 7741-7746 [PMID: 24821797 DOI: 10.1073/pnas.1407001111]

36 **Murthy A**, Li Y, Peng I, Reichelt M, Katakam AK, Noubade R, Roose-Girma M, DeVoss J, Diehl L, Graham RR, van Lookeren Campagne M. A Crohn's disease variant in Atg16l1 enhances its degradation by caspase 3. *Nature* 2014; **506**: 456-462 [PMID: 24553140 DOI: 10.1038/nature13044]

37 **Cadwell K**, Patel KK, Maloney NS, Liu TC, Ng AC, Storer CE, Head RD, Xavier R, Stappenbeck TS, Virgin HW. Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. *Cell* 2010; **141**: 1135-1145 [PMID: 20602997 DOI: 10.1016/j.cell.2010.05.009]

38 **Chu H**, Khosravi A, Kusumawardhani IP, Kwon AH, Vasconcelos AC, Cunha LD, Mayer AE, Shen Y, Wu WL, Kambal A, Targan SR, Xavier RJ, Ernst PB, Green DR, McGovern DP, Virgin HW, Mazmanian SK. Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease. *Science* 2016; **352**: 1116-1120 [PMID: 27230380 DOI: 10.1126/science.aad9948]

39 **Parkes M**, Barrett JC, Prescott NJ, Tremelling M, Anderson CA, Fisher SA, Roberts RG, Nimmo ER, Cummings FR, Soars D, Drummond H, Lees CW, Khawaja SA, Bagnall R, Burke DA, Todhunter CE, Ahmad T, Onnie CM, McArdle W, Strachan D, Bethel G, Bryan C, Lewis CM, Deloukas P, Forbes A, Sanderson J, Jewell DP, Satsangi J, Mansfield JC, Cardon L, Mathew CG. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. *Nat Genet* 2007; **39**: 830-832 [PMID: 17554261 DOI: 10.1038/ng2061]

40 **Singh SB**, Davis AS, Taylor GA, Deretic V. Human IRGM induces autophagy to eliminate intracellular mycobacteria. *Science* 2006; **313**: 1438-1441 [PMID: 16888103 DOI: 10.1126/science.1129577]

41 **McCarroll SA**, Huett A, Kuballa P, Chilewski SD, Landry A, Goyette P, Zody MC, Hall JL, Brant SR, Cho JH, Duerr RH, Silverberg MS, Taylor KD, Rioux JD, Altshuler D, Daly MJ, Xavier RJ. Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. *Nat Genet* 2008; **40**: 1107-1112 [PMID: 19165925 DOI: 10.1038/ng.215]

42 **Rufini S**, Ciccacci C, Di Fusco D, Ruffa A, Pallone F, Novelli G, Biancone L, Borgiani P. Autophagy and inflammatory bowel disease: Association between variants of the autophagy-related IRGM gene and susceptibility to Crohn's disease. *Dig Liver Dis* 2015; **47**: 744-750 [PMID: 26066377 DOI: 10.1016/j.dld.2015.05.012]

43 **Fitch E**, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. *Curr Rheumatol Rep* 2007; **9**: 461-467 [PMID: 18177599]

44 **McGovern D**, Powrie F. The IL23 axis plays a key role in the pathogenesis of IBD. *Gut* 2007; **56**: 1333-1336 [PMID: 17872562 DOI: 10.1136/gut.2006.115402]

45 **Yen D**, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, Kleinschek MA, Owyang A, Mattson J, Blumenschein W, Murphy E, Sathe M, Cua DJ, Kastelein RA, Rennick D. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. *J Clin Invest* 2006; **116**: 1310-1316 [PMID: 16670770 DOI: 10.1172/JCI21404]

46 **Parham C**, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, Pflanz S, Zhang R, Singh KP, Vega F, To W, Wagner J, O'Farrell AM, McClanahan T, Zurawski S, Hannum C, Gorman D, Rennick DM, Kastelein RA, de Waal Malefyt R, Moore KW. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. *J Immunol* 2002; **168**: 5699-5708 [PMID: 12023369 DOI: 10.4049/jimmunol.168.11.5699]

47 **Bianco AM**, Girardelli M, Tommasini A. Genetics of inflammatory bowel disease from multifactorial to monogenic forms. *World J Gastroenterol* 2015; **21**: 12296-12310 [PMID: 26604638 DOI: 10.3748/wjg.v21.i43.12296]

48 **Fuyuno Y**, Yamazaki K, Takahashi A, Esaki M, Kawaguchi T, Takazoe M, Matsumoto T, Matsui T, Tanaka H, Motoya S, Suzuki Y, Kiyohara Y, Kitazono T, Kubo M. Genetic characteristics of inflammatory bowel disease in a Japanese population. *J Gastroenterol* 2016; **51**: 672-681 [PMID: 26511940 DOI: 10.1007/s00535-015-1135–3]

49 **Peral de Castro C**, Jones SA, Ní Cheallaigh C, Hearnden CA, Williams L, Winter J, Lavelle EC, Mills KH, Harris J. Autophagy regulates IL-23 secretion and innate T cell responses through effects on IL-1 secretion. *J Immunol* 2012; **189**: 4144-4153 [PMID: 22972933 DOI: 10.4049/jimmunol.1201946]

50 **Crook NE**, Clem RJ, Miller LK. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. *J Virol* 1993; **67**: 2168-2174 [PMID: 8445726]

51 **Eckelman BP**, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. *EMBO Rep* 2006; **7**: 988-994 [PMID: 17016456 DOI: 10.1038/sj.embor.7400795]

52 **Mizushima N**, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. *Nature* 2008; **451**: 1069-1075 [PMID: 18305538 DOI: 10.1038/nature06639]

53 **Huang X**, Wu Z, Mei Y, Wu M. XIAP inhibits autophagy via XIAP-Mdm2-p53 signalling. *EMBO J* 2013; **32**: 2204-2216 [PMID: 23749209 DOI: 10.1038/emboj.2013.133]

54 **Zeissig Y**, Petersen BS, Milutinovic S, Bosse E, Mayr G, Peuker K, Hartwig J, Keller A, Kohl M, Laass MW, Billmann-Born S, Brandau H, Feller AC, Röcken C, Schrappe M, Rosenstiel P, Reed JC, Schreiber S, Franke A, Zeissig S. XIAP variants in male Crohn's disease. *Gut* 2015; **64**: 66-76 [PMID: 24572142 DOI: 10.1136/gutjnl-2013-306520]

55 **Schwerd T**, Pandey S, Yang HT, Bagola K, Jameson E, Jung J, Lachmann RH, Shah N, Patel SY, Booth C, Runz H, Düker G, Bettels R, Rohrbach M, Kugathasan S, Chapel H, Keshav S, Elkadri A, Platt N, Muise AM, Koletzko S, Xavier RJ, Marquardt T, Powrie F, Wraith JE, Gyrd-Hansen M, Platt FM, Uhlig HH. Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann-Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn's disease. *Gut* 2016; Epub ahead of print [PMID: 26953272 DOI: 10.1136/gutjnl-2015-310382]

56 **Alegre-Abarrategui J**, Christian H, Lufino MM, Mutihac R, Venda LL, Ansorge O, Wade-Martins R. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. *Hum Mol Genet* 2009; **18**: 4022-4034 [PMID: 19640926 DOI: 10.1093/hmg/ddp346]

57 **Barrett JC**, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwilliam R, Tremelling M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. *Nat Genet* 2008; **40**: 955-962 [PMID: 18587394 DOI: 10.1038/ng.175]

58 **Gardet A**, Benita Y, Li C, Sands BE, Ballester I, Stevens C, Korzenik JR, Rioux JD, Daly MJ, Xavier RJ, Podolsky DK. LRRK2 is involved in the IFN-gamma response and host response to pathogens. *J Immunol* 2010; **185**: 5577-5585 [PMID: 20921534 DOI: 10.4049/jimmunol.1000548]

59 **Henckaerts L**, Cleynen I, Brinar M, John JM, Van Steen K, Rutgeerts P, Vermeire S. Genetic variation in the autophagy gene ULK1 and risk of Crohn's disease. *Inflamm Bowel Dis* 2011; **17**: 1392-1397 [PMID: 21560199 DOI: 10.1002/ibd.21486]

60 **Kim J**, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. *Nat Cell Biol* 2011; **13**: 132-141 [PMID: 21258367 DOI: 10.1038/ncb2152]

61 **Lee JW**, Park S, Takahashi Y, Wang HG. The association of AMPK with ULK1 regulates autophagy. *PLoS One* 2010; **5**: e15394 [PMID: 21072212 DOI: 10.1371/journal.pone.0015394]

62 **Pei FH**, Wang YJ, Gao SL, Liu BR, DU YJ, Liu W, Yu HY, Zhao LX, Chi BR. Vitamin D receptor gene polymorphism and ulcerative colitis susceptibility in Han Chinese. *J Dig Dis* 2011; **12**: 90-98 [PMID: 21401893 DOI: 10.1111/j.1751-2980.2011.00483.x]

63 **Simmons JD**, Mullighan C, Welsh KI, Jewell DP. Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility. *Gut* 2000; **47**: 211-214 [PMID: 10896912]

64 **Wu S**, Zhang YG, Lu R, Xia Y, Zhou D, Petrof EO, Claud EC, Chen D, Chang EB, Carmeliet G, Sun J. Intestinal epithelial vitamin D receptor deletion leads to defective autophagy in colitis. *Gut* 2015; **64**: 1082-1094 [PMID: 25080448 DOI: 10.1136/gutjnl-2014-307436]

65 **Abreu-Delgado Y**, Isidro RA, Torres EA, González A, Cruz ML, Isidro AA, González-Keelan CI, Medero P, Appleyard CB. Serum vitamin D and colonic vitamin D receptor in inflammatory bowel disease. *World J Gastroenterol* 2016; **22**: 3581-3591 [PMID: 27053850 DOI: 10.3748/wjg.v22.i13.3581]

66 **Henderson P**, van Limbergen JE, Wilson DC, Satsangi J, Russell RK. Genetics of childhood-onset inflammatory bowel disease. *Inflamm Bowel Dis* 2011; **17**: 346-361 [PMID: 20839313 DOI: 10.1002/ibd.21283]

67 **Franke A**, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C, Cohen A, Colombel JF, Cottone M, Stronati L, Denson T, De Vos M, D'Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Gearry R, Glas J, Van Gossum A, Guthery SL, Halfvarson J, Verspaget HW, Hugot JP, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, Mowat C, Newman W, Panés J, Phillips A, Proctor DD, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, Stokkers PC, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD, D'Amato M, Weersma RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr RH, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ, Parkes M. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. *Nat Genet* 2010; **42**: 1118-1125 [PMID: 21102463 DOI: 10.1038/ng.717]

68 **Lahiri A**, Hedl M, Abraham C. MTMR3 risk allele enhances innate receptor-induced signaling and cytokines by decreasing autophagy and increasing caspase-1 activation. *Proc Natl Acad Sci U S A* 2015; **112**: 10461-10466 [PMID: 26240347 DOI: 10.1073/pnas.1501752112]

69 **Yamamoto-Furusho JK**, Peñaloza-Coronel A, Sánchez-Muñoz F, Barreto-Zuñiga R, Dominguez-Lopez A. Peroxisome proliferator-activated receptor-gamma (PPAR-γ) expression is downregulated in patients with active ulcerative colitis. *Inflamm Bowel Dis* 2011; **17**: 680-681 [PMID: 20848495 DOI: 10.1002/ibd.21322]

70 **Rousseaux C**, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. *J Exp Med* 2005; **201**: 1205-1215 [PMID: 15824083 DOI: 10.1084/jem.20041948]

71 **Chacon-Cabrera A**, Fermoselle C, Urtreger AJ, Mateu-Jimenez M, Diament MJ, de Kier Joffé ED, Sandri M, Barreiro E. Pharmacological strategies in lung cancer-induced cachexia: effects on muscle proteolysis, autophagy, structure, and weakness. *J Cell Physiol* 2014; **229**: 1660-1672 [PMID: 24615622 DOI: 10.1002/jcp.24611]

72 **Kuenzig ME**, Rezaie A, Seow CH, Otley AR, Steinhart AH, Griffiths AM, Kaplan GG, Benchimol EI. Budesonide for maintenance of remission in Crohn's disease. *Cochrane Database Syst Rev* 2014;**(8):** CD002913 [PMID: 25141071 DOI: 10.1002/14651858.CD002913.pub3]

73 **Polman JA**, Hunter RG, Speksnijder N, van den Oever JM, Korobko OB, McEwen BS, de Kloet ER, Datson NA. Glucocorticoids modulate the mTOR pathway in the hippocampus: differential effects depending on stress history. *Endocrinology* 2012; **153**: 4317-4327 [PMID: 22778218 DOI: 10.1210/en.2012-1255]

74 **Wang H**, Kubica N, Ellisen LW, Jefferson LS, Kimball SR. Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1. *J Biol Chem* 2006; **281**: 39128-39134 [PMID: 17074751 DOI: 10.1074/jbc.M610023200]

75 **Swerdlow S**, McColl K, Rong Y, Lam M, Gupta A, Distelhorst CW. Apoptosis inhibition by Bcl-2 gives way to autophagy in glucocorticoid-treated lymphocytes. *Autophagy* 2008; **4**: 612-620 [PMID: 18362516]

76 **Jia G**, Cheng G, Gangahar DM, Agrawal DK. Insulin-like growth factor-1 and TNF-alpha regulate autophagy through c-jun N-terminal kinase and Akt pathways in human atherosclerotic vascular smooth cells. *Immunol Cell Biol* 2006; **84**: 448-454 [PMID: 16942488 DOI: 10.1111/j.1440-1711.2006.01454.x]

77 **Xia X**, Kar R, Gluhak-Heinrich J, Yao W, Lane NE, Bonewald LF, Biswas SK, Lo WK, Jiang JX. Glucocorticoid-induced autophagy in osteocytes. *J Bone Miner Res* 2010; **25**: 2479-2488 [PMID: 20564240 DOI: 10.1002/jbmr.160]

78 **Guijarro LG**, Román ID, Fernández-Moreno MD, Gisbert JP, Hernández-Breijo B. Is the autophagy induced by thiopurines beneficial or deleterious? *Curr Drug Metab* 2012; **13**: 1267-1276 [PMID: 22493985]

79 **Wang L**, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. *Oncogene* 2006; **25**: 1629-1638 [PMID: 16550163 DOI: 10.1038/sj.onc.1209372]

80 **Evans WE**, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. *J Pediatr* 1991; **119**: 985-989 [PMID: 1960624]

81 **Lennard L**, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. *Clin Pharmacol Ther* 1989; **46**: 149-154 [PMID: 2758725]

82 **Schaeffeler E**, Fischer C, Brockmeier D, Wernet D, Moerike K, Eichelbaum M, Zanger UM, Schwab M. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. *Pharmacogenetics* 2004; **14**: 407-417 [PMID: 15226673]

83 **Schütz E**, Gummert J, Mohr F, Oellerich M. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. *Lancet* 1993; **341**: 436 [PMID: 8094196]

84 **Li F**, Wang L, Burgess RJ, Weinshilboum RM. Thiopurine S-methyltransferase pharmacogenetics: autophagy as a mechanism for variant allozyme degradation. *Pharmacogenet Genomics* 2008; **18**: 1083-1094 [PMID: 18820593 DOI: 10.1097/FPC.0b013e328313e03f]

85 **Markowitz J**, Grancher K, Kohn N, Daum F. Immunomodulatory therapy for pediatric inflammatory bowel disease: changing patterns of use, 1990-2000. *Am J Gastroenterol* 2002; **97**: 928-932 [PMID: 12003428 DOI: 10.1111/j.1572-0241.2002.05611.x]

86 **Nuki Y**, Esaki M, Asano K, Maehata Y, Umeno J, Moriyama T, Nakamura S, Matsumoto T, Kitazono T. Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience. *Scand J Gastroenterol* 2016; **51**: 700-705 [PMID: 26818468 DOI: 10.3109/00365521.2016.1138239]

87 **Pallet N**, Bouvier N, Legendre C, Gilleron J, Codogno P, Beaune P, Thervet E, Anglicheau D. Autophagy protects renal tubular cells against cyclosporine toxicity. *Autophagy* 2008; **4**: 783-791 [PMID: 18628650]

88 **Kimura T**, Takahashi A, Takabatake Y, Namba T, Yamamoto T, Kaimori JY, Matsui I, Kitamura H, Niimura F, Matsusaka T, Soga T, Rakugi H, Isaka Y. Autophagy protects kidney proximal tubule epithelial cells from mitochondrial metabolic stress. *Autophagy* 2013; **9**: 1876-1886 [PMID: 24128672 DOI: 10.4161/auto.25418]

89 **Kim HS**, Choi SI, Jeung EB, Yoo YM. Cyclosporine A induces apoptotic and autophagic cell death in rat pituitary GH3 cells. *PLoS One* 2014; **9**: e108981 [PMID: 25299210 DOI: 10.1371/journal.pone.0108981]

90 **Liu J**, Albers MW, Wandless TJ, Luan S, Alberg DG, Belshaw PJ, Cohen P, MacKintosh C, Klee CB, Schreiber SL. Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. *Biochemistry* 1992; **31**: 3896-3901 [PMID: 1373650]

91 **Jung CH**, Jun CB, Ro SH, Kim YM, Otto NM, Cao J, Kundu M, Kim DH. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. *Mol Biol Cell* 2009; **20**: 1992-2003 [PMID: 19225151 DOI: 10.1091/mbc.E08-12-1249]

92 **Ganley IG**, Lam du H, Wang J, Ding X, Chen S, Jiang X. ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy. *J Biol Chem* 2009; **284**: 12297-12305 [PMID: 19258318 DOI: 10.1074/jbc.M900573200]

93 **de Ridder L**, Waterman M, Turner D, Bronsky J, Hauer AC, Dias JA, Strisciuglio C, Ruemmele FM, Levine A, Lionetti P. Use of Biosimilars in Paediatric Inflammatory Bowel Disease: A Position Statement of the ESPGHAN Paediatric IBD Porto Group. *J Pediatr Gastroenterol Nutr* 2015; **61**: 503-508 [PMID: 26154031 DOI: 10.1097/MPG.0000000000000903]

94 **Connor AM**, Mahomed N, Gandhi R, Keystone EC, Berger SA. TNFα modulates protein degradation pathways in rheumatoid arthritis synovial fibroblasts. *Arthritis Res Ther* 2012; **14**: R62 [PMID: 22417670 DOI: 10.1186/ar3778]

95 **Keller CW**, Fokken C, Turville SG, Lünemann A, Schmidt J, Münz C, Lünemann JD. TNF-alpha induces macroautophagy and regulates MHC class II expression in human skeletal muscle cells. *J Biol Chem* 2011; **286**: 3970-3980 [PMID: 20980264 DOI: 10.1074/jbc.M110.159392]

96 **Cha HH**, Hwang JR, Kim HY, Choi SJ, Oh SY, Roh CR. Autophagy induced by tumor necrosis factor α mediates intrinsic apoptosis in trophoblastic cells. *Reprod Sci* 2014; **21**: 612-622 [PMID: 24198074 DOI: 10.1177/1933719113508816]

97 **Nys K**, Agostinis P, Vermeire S. Autophagy: a new target or an old strategy for the treatment of Crohn's disease? *Nat Rev Gastroenterol Hepatol* 2013; **10**: 395-401 [PMID: 23591407 DOI: 10.1038/nrgastro.2013.66]

**P-Reviewer:** Bezmin Abadi AT, de Almeida Araujo EJ, Patial V **S-Editor:** Qi Y **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Japan

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Figure 1 Autophagy mechanism.** The autophagy pathway. During this process, the endoplasmic reticulum or other membranous cellular structures respond to stimuli by generating a double-membrane structure called a phagophore. On this phagophore, *ATG16L1* forms a complex with an *ATG5-ATG12* conjugate, which multimerizes and then lipidates LC3 (LC3-II). Simultaneously, the phagophore elongates to envelop the cytoplasm or organelle to be degraded, forming an autophagosome, a unique double-membrane organelle. The outer membrane of the autophagosome then fuses with a lysosome to form an autolysosome, and the inner membrane degrades and absorbs its contents.

**Table 1 Genetic variants related to inflammatory bowel disease and autophagy**

|  |  |  |
| --- | --- | --- |
| **Gene** | **Chromosomal site** | **Relation to autophagy** |
| *NOD2* | 16q12.1 | Intracellular bacterial sensing |
|  |  | Autophagosome formation |
| *ATG16L1* | 2p37.1 | Autophagosome formation |
|  |  | Suppressing Paneth cells |
| *IRGM* | 5q33.1 | Phagosome maturation |
|  |  | Virus-induced autophagy |
| *IL-23R* | 1p31.3 | Through effects on IL-1 secretion |
| *XIAP* | Xq25 | Physiological inhibitor of autophagy |
| *LRRK2* | 12q12 | Autophagosomal-lysosomal degradation  |
| *ULK1* | 12q24.33 | Regulated by TORC1 and AMPK |
| *VDR* | 12q13.11 | Regulate the expression of *NOD2* |
| *MTMR3* | 22q12.2 | Autophagosome formation |

**Table 2 Therapeutic agents for inflammatory bowel disease related to autophagy**

|  |  |  |
| --- | --- | --- |
| **Drug** | **Influence on autophagy** | **Mechanism related to autophagy** |
| 5-ASA | Promotion | Through NF-κB signaling pathway |
| Corticosteroid | Promotion | Through NF-κB signaling pathway |
|  |  | Through mTORC1 signaling pathway |
|  |  | Through overexpression of Bcl-2 |
|  |  |  in immature T-lymphocytes |
|  |  | Osteocyte viability |
| Thiopurine | Promotion |  Clearance of TPMT\*3A aggregates  |
| (AZA, 6-MP) |  |  and/or aggregate precursors |
|  |  |  Protective role in hepatocytes |
| Immunomodulatory drugs | Promotion | Response to toxicity |
| (CsA, FK506) |  | Through mTORC1 signaling pathway |
| Biological drugs | Inhibition | Anti-TNF agents inhibit  |
| (IFX, ADA, etc.) | 　 | autophagy (not yet clear) |
| 5-ASA: 5-aminosalicylic acid; mTORC1: Mechanistic target of rapamycin complex 1; |
| AZA: Azathioprine; 6-MP: 6-Mercaptopurine; TPMT: Thiopurine S-methyltransferase; |
| CsA: Cyclosporine A; IFX: Infliximab; ADA: Adalimumab; TNF: Tumor necrosis factor. |